Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Amycretin in Renal Impairment
NCT06559527Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amycretin in type 2 diabetes mellitus (T2DM), obesity and Overweight (5 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity. Started Aug 2024; status: completed.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on NCT06559527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06559527.